Red Light Therapy at Home: What Determines Whether It Works or Not

When someone searches for “red light therapy at home” or “red light panel”, they are usually no longer at the very beginning. They know that red and near-infrared light exist, they have heard of photobiomodulation, and they may already be comparing specific devices. At this point, however, something important can happen very easily: the question “What am I trying to achieve, and what optical stimulus do I need to achieve it?” turns into “Which panel is the most powerful?”

That is where most misunderstandings begin.

At-home red light therapy is not simply a question of whether you own a high-quality device. The device matters greatly because it determines spectrum, irradiance, light-field geometry, treatment area, output stability and the possibilities for controlling dose. But even the best technical specification is not yet a biological outcome. Between the panel and the result lie a specific exposure, a specific tissue and the biological response of the person receiving it.

The most useful way to think about red light therapy at home is therefore through a simple sequence:

OBJECTIVE → OPTICAL STIMULUS → DOSE → TARGET TISSUE → BIOLOGICAL RESPONSE → OUTCOME

If we do not understand one of these layers, it becomes very easy to judge photobiomodulation by asking the wrong question.

So, does red light therapy work at home?

Yes — at-home photobiomodulation can be biologically and clinically relevant, but it is not reasonable to assume that any red light panel will work for any objective. Systematic reviews of home-use PBM devices have already reported favourable outcomes for selected applications. A 2026 systematic review of at-home LED devices for facial rejuvenation included eight studies and 365 participants; improvements were reported across several parameters of skin ageing, while adverse events were predominantly mild and transient. At the same time, the authors highlighted differences between protocols, the lack of direct device-to-device comparisons and the need for larger, better-standardised studies.

An even broader perspective comes from a 2026 umbrella review covering 100 systematic reviews representing 790 unique primary studies. Most reviews reported favourable conclusions for at least some of the outcomes examined, but the methodological confidence of a large proportion of those systematic reviews was rated low or critically low. The authors therefore support the possibility of clinical benefit in selected indications, not the universal effectiveness of “red light therapy” as though it were one homogeneous intervention.

That distinction is crucial. The question “Does red light therapy work?” is too broad. A much more precise question is:

Does this specific optical exposure, delivered at this specific dose, reach the relevant target tissue and produce the particular outcome I am trying to achieve?

Only then does it make sense to choose a panel.

The first thing that matters: what do you actually expect light to do?

Red light therapy is now marketed so broadly that completely different biological objectives are often placed under one label. Skin, hair, muscles, pain, post-exercise recovery, wound healing, joints, sleep, “energy”, immunity and even vague promises of whole-body rejuvenation can all appear on the same product page.

That does not mean that all of these objectives are supported by evidence of equal quality, or that they should all be approached with the same protocol.

An international evidence-based consensus published in 2025 described PBM as a safe modality for adults when appropriately used and supported its application in several specific clinical indications, including androgenetic alopecia, peripheral neuropathy, selected ulcerations and acute radiation dermatitis. That does not mean that the same panel, the same dose and the same method of use are automatically appropriate for all of these applications.

Similarly, a 2025 umbrella review of randomised trials included 204 RCTs and more than 9,000 participants. Statistically significant effects were found for some outcomes, while certainty of evidence remained low or very low for many others.

For someone considering home use, the practical principle is straightforward:

Define the objective first. Only then choose the device, dose and protocol.

A panel cannot meaningfully be described as “the best” until we know what it is supposed to be best for.

The second thing that matters: what light actually reaches the body

Product pages make it easy to compare LED counts, electrical power, maximum output or the number of wavelengths used. Biological exposure, however, is not created by a list of components.

What matters is the light that actually reaches the treatment area at a realistic working distance.

Key parameters in photobiomodulation therefore include wavelength and spectral composition, irradiance, the size and uniformity of the light field, source geometry, distance, exposure duration, continuous or pulsed operation, and the number and frequency of repeated exposures. Scientific literature has long highlighted the enormous variability in these parameters as one of the reasons PBM study results can differ so substantially.

An even more fundamental issue is that older PBM literature often reported technical parameters incompletely or inaccurately. Analyses of radiometric reporting have identified substantial missing information relating to irradiance, beam area, radiant energy, pulsing and other variables, making reproducibility considerably more difficult.

For a home-use device, therefore, the most important statement is not:

“It has 300 LEDs.”

A far more useful question is:

What measurable, uniform and reproducible optical exposure does it create on the body at the working distance at which it is actually intended to be used?

Irradiance is not dose — and joules alone are still not the whole story

Three different concepts are frequently confused in home red light panels: device power, irradiance and dose.

Irradiance describes the optical power reaching a unit area and is typically expressed in mW/cm². Radiant exposure, often referred to as fluence, describes the amount of optical energy delivered per unit area and is typically expressed in J/cm².

Put simply, irradiance tells us how intense the optical exposure is at a given moment, whereas radiant exposure tells us how much light energy that area receives over the full duration of the exposure.

In simplified form:

radiant exposure (J/cm²) = irradiance (W/cm²) × time (s)

This equation matters because it explains why time alone tells us very little without knowing irradiance. Ten minutes in front of two different panels may represent completely different optical exposures.

Even identical values in J/cm² do not automatically guarantee the same biological outcome. Spectrum, the manner in which the energy is delivered, irradiance level, illuminated area, temporal structure of the exposure, target tissue and other variables can all alter the biological response. Modern PBM reviews therefore emphasise light–tissue interaction, target-tissue composition and rationalised dosing, rather than relying on one number shown on a device display.

For TANVEA, this leads to a fundamental principle:

Technical output is a property of the device. Dose is a property of a specific exposure.

And exposure is what the user needs to be able to control.

Why a more powerful panel is not necessarily a better panel

Higher power can be a technical advantage. It can provide operating headroom, allow use at greater distances, cover a larger area or make it possible to alter exposure time. But it does not follow that biologically optimal use always means setting the device to maximum output and standing as close as possible.

Photobiomodulation is one of the fields in which a biphasic dose response has long been discussed. In simplified terms, an exposure that is too low may fail to create a sufficient stimulus, an appropriate range may generate the desired biological response, and further increasing exposure does not necessarily improve the result — in some experimental models, it may even reduce it.

The statement “more is better” is therefore not a reliable biological principle in red light therapy.

The opposite myth should not be created either. High output is not automatically bad. The relevant question is not whether a panel is marketed as “powerful” or “gentle”, but what exposure it allows us to create and whether that exposure can be controlled.

Distance from the panel is not a magic number

The internet is full of charts such as “20 cm for muscle, 50 cm for skin”. Without knowing the specific optical system, however, such recommendations cannot be universally valid.

Changing distance changes irradiance and, in multi-LED panels, also changes how the individual beams overlap in space. This can affect not only intensity but also the uniformity of exposure across a large area of the body. A panel placed too close may create high local peaks and an uneven field; another optical design may behave differently.

A manufacturer’s statement such as “use at 15–30 cm” is therefore not, by itself, an adequate description of the optical system unless we know what irradiance and spatial light distribution the device creates across those distances.

A protocol developed for one panel should not be copied to another simply because both devices emit red light.

Spectrum matters — but more wavelengths do not automatically mean more biological value

Red light therapy usually works within the red and near-infrared portions of the spectrum. Different wavelengths have different absorption and penetration characteristics and can interact with tissue in different ways.

That does not mean that a panel listing more wavelengths is automatically biologically superior.

Six wavelengths are not inherently better than two, and two are not automatically better than one. What matters is why those wavelengths were selected, the proportion in which they are represented, the irradiance contributed by each spectral component and how the complete architecture relates to its intended use.

Modern PBM reviews continue to discuss mitochondrial and redox signalling, cytochrome c oxidase, nitric oxide, ion channels, Ca²⁺ and other mechanisms, while at the same time showing that the biological response is much more complex than a simple model of “one wavelength → one effect”.

Good optical architecture is therefore not created by collecting as many nanometres as possible.

It is created through biological and optical logic.

Target tissue matters more than it may seem in home use

Light must first travel through the environment between the source and the biological structure we are trying to influence. Skin, pigment, hair, subcutaneous fat, blood, water and other tissue components absorb and scatter light. This is why there is no single universal dose “for the body”.

A panel therefore does not irradiate a fixed “depth in centimetres”. It creates an optical field at the surface of the body, and the amount of light that subsequently reaches a deeper target is determined by how that light interacts with the tissues along its path.

This is particularly important when treating the scalp. A panel may emit an appropriate spectrum, but if much of the light is blocked by the hair and the exposure reaching the scalp is substantially different, the technical specification of the panel still does not tell us what the target structure actually receives.

The same principle applies to deeper tissues. A photon reaching the surface of the skin is not the same as an equivalent amount of energy reaching a muscle, joint or another deeper structure.

This is why PBM is not only about nanometres and joules. Light–tissue interaction and the anatomical target matter.

The same panel may not produce the same result in every person — but not because the body has to be “prepared”

A person’s biological state can influence the eventual response. Cells in healthy and stressed states may not respond identically to the same optical stimulus, and mechanistic literature describes different redox responses depending on the initial cellular condition.

This does not, however, mean that a person must first have “restored flow”, a “relaxed body” or specifically increased oxygenation before PBM can work. Nor do we have universal clinical evidence showing that sauna, hydrotherapy, oxygen exposure or another modality used before light automatically amplifies its effect.

That would confuse systems-based biological thinking with unproven synergy.

A more precise TANVEA framework is:

An optical stimulus enters a specific biological environment. That context may influence the response, but it should not be turned into a universal list of prerequisites that must be fulfilled before PBM can work.

TANVEA Biological Systems™ therefore do not imply a mandatory Hydro → Thermal → Light → Oxygen → Hydrogen sequence.

They reflect the understanding that every physical stimulus enters the same living organism — and that each modality should be understood precisely within its own biological role.

Consistency matters. But frequency is not universal either.

At-home photobiomodulation has one major practical advantage: it allows repeated exposure without the need for regular visits to a specialised facility.

That same advantage can easily create another misunderstanding. If three sessions per week make sense, six must be better. If ten minutes work, twenty must work faster.

Biological dosing does not work that way.

Frequency and the interval between exposures are part of the protocol just as much as the dose delivered during an individual session. Different indications and devices use very different schedules in research studies, and this heterogeneity is one of the main reasons there is no scientifically responsible universal rule that says “use red light therapy X times per week”.

For home use, reasonable consistency within a well-defined protocol is therefore more valuable than continually increasing frequency according to subjective impressions.

The outcome should be judged according to the objective — not by whether you “feel something” after the first session

Red light therapy has another unusual feature: many people expect an immediate subjective sensation that confirms the device is working.

But a biological effect does not need to be accompanied by a strong sensation, and different objectives operate on very different biological timescales.

Some outcomes may be evaluated after individual exposures or over a relatively short period. For hair, skin or longer-term adaptation, relevant timescales may extend over weeks or months. More recent reviews of consumer red light claims also point out that where evidence does exist, improvements are often gradual and relatively modest, while marketing frequently exaggerates the speed, magnitude and durability of the effect.

The question:

“Did I feel anything after ten minutes?”

is therefore not a useful universal test.

A better question is:

“What outcome am I tracking, how will I measure it, and after what period does it make biological sense to evaluate it?”

The most common reasons why at-home red light therapy disappoints

When home use does not produce the expected outcome, the explanation does not have to be that “red light therapy does not work”. But it is equally inappropriate to assume that the user must be doing something wrong.

The problem may lie in an incorrectly chosen objective, weak evidence for the intended application, unsuitable spectrum or device geometry, unknown actual irradiance, an exposure that is too low or too high, copying a protocol from another panel, inconsistent use, evaluating the result too early, or expecting an outcome that light alone cannot produce.

And sometimes the problem may simply be the device itself.

TANVEA therefore does not want to create the opposite extreme in which every disappointing result is blamed on an “unprepared body”.

Technology must also carry its share of responsibility.

What should a good red light panel for home use look like?

A good panel should be more than an impressive list of components. It should allow the user to understand what exposure it creates and how that exposure can be repeated safely.

When evaluating a system, it therefore makes sense to consider spectral composition, actual irradiance at practical working distances, light-field uniformity, treatment area, optics and geometry, the ability to control power and time, output stability and reproducibility, thermal comfort, safety guidance and serviceability.

Marketing claims such as “300 W”, “1,000 LEDs” or “7 wavelengths” are insufficient without this context.

It is also important to know how irradiance was measured. Radiometry for LED and laser systems is not trivial, and poor methodology can produce a number that looks extremely precise while failing to represent the actual optical exposure accurately.

For TANVEA, the goal is therefore not to create the panel with the largest number on the product page.

The goal is to create a controllable optical environment.

This is why the development of TANVEA Light Systems™ does not begin with the question of how many LEDs or watts can be fitted into a device. It begins with the question of what optical environment needs to be created at the human body. Spectrum, irradiance, geometry, working distance, light-field uniformity and dose control are therefore not treated as isolated technical specifications, but as one integrated optical architecture.

The user does not need a panel with the biggest number. The user needs a system that makes it possible to know what optical stimulus is actually being delivered.

What about mitochondria and ATP?

Red light therapy is often explained by saying that light “gives cells energy”. The phrase is easy to understand, but biologically it is inaccurate.

Light is not fuel, and photons are not converted directly into ATP.

Under appropriate exposure conditions, red and near-infrared light can influence cellular and mitochondrial signalling. Among the most extensively studied mechanistic areas are cytochrome c oxidase, nitric oxide, redox signalling, ROS, Ca²⁺ and downstream regulatory processes that can influence cellular metabolism and gene expression.

Increases in ATP have been observed in many experimental models, but it would be inaccurate to claim that every exposure to red or near-infrared light automatically increases ATP in every person, or that ATP explains every clinical outcome associated with PBM.

Mitochondria also do not require red light for normal ATP production. Photobiomodulation is a modulatory physical stimulus, not a fundamental requirement of human bioenergetics.

This distinction matters in at-home red light therapy as well. Light is not fuel, it is not ATP, and it is not “energy for cells” in the same sense as metabolic substrates. It is a physical input that, under appropriate conditions, may alter cellular signalling and the biological response that follows.

Home use does not make safety irrelevant

Using a device at home does not change the physics of light.

An evidence-based consensus published in 2025 describes PBM as a generally safe modality for adults when appropriately used. Safety, however, cannot be separated from the specific device, exposure parameters, anatomical region and method of use.

Eye exposure deserves particular attention. “Red light” is not one universal category of optical devices, and safety rules cannot simply be transferred from one system to another. For devices designed to irradiate the body, users should follow the manufacturer’s eye-safety instructions and should not experiment with prolonged direct viewing of high-output LED emitters.

Individual professional consultation is also appropriate in situations involving photosensitivity, photosensitising medication, significant ocular disease, serious medical conditions, or the use of PBM with the intention of influencing a diagnosed disease.

A red light panel can be a home wellness tool.

It should not become a substitute for diagnosis.

The TANVEA framework for red light therapy at home

If the entire article is reduced to one model, TANVEA no longer uses the older logic:

panel → prepared body → effect

A more accurate framework is:

OBJECTIVE

What are you actually trying to influence, and what quality of evidence exists for that objective?

↓

OPTICAL STIMULUS

What spectrum, irradiance, geometry and uniformity does the specific device create?

↓

DOSE

What exposure is created at a particular distance, output setting and duration, and how often is it repeated?

↓

TARGET TISSUE

Where does the light need to reach, and what optical and anatomical conditions lie between the source and the target?

↓

BIOLOGICAL RESPONSE

How do the specific tissue and the organism respond to the stimulus?

↓

OUTCOME

Are we measuring the right variable, and are we allowing enough time for that variable to change?

This model is less dramatic than saying “buy the most powerful panel”.

But it is much closer to biological reality.

So what determines whether red light therapy at home will work?

It is not one single factor. It is not LED count, maximum irradiance or the number of wavelengths. Nor is it some vague idea of the body being “prepared”.

What matters is the alignment between the objective, quality of evidence, the optical architecture of the device, actual exposure, dose, target tissue, method of use, safety, and the way the outcome is evaluated over time.

At-home red light therapy can therefore be a very interesting tool. Precisely for that reason, it deserves more than marketing comparisons of wattage.

A good panel does not create the outcome. It creates a well-defined optical stimulus. The outcome emerges only through the interaction between that stimulus and the specific biological target.

That is the difference between light as an appliance and light as a system.

Red light therapy at home makes more sense when you understand more than panel power

If you are considering an at-home red light system, do not begin only by asking which panel is the most powerful. Begin by asking what you want the light to influence, what biological objective you are pursuing, and whether the device can create a defined and reproducible exposure appropriate for that purpose.

At TANVEA Light Systems™, we therefore do not view the panel as a glowing appliance. We view the entire light system — spectrum, irradiance, geometry, dose, working distance, target tissue, safety and method of use.

If you want to understand the difference between marketing power and controlled optical exposure, you can continue into the deeper TANVEA Library → LIGHT SYSTEMS layer or experience the principles of a designed light system directly at TANVEA Experience Space™.


FAQ

Does red light therapy work at home?

It can, but the result depends on the specific objective, device and protocol. At-home PBM devices have favourable clinical data for selected applications, but the results of one device or one indication cannot automatically be generalised to every red light panel and every objective.

What is the best red light panel for home use?

There is no single universally best panel. What matters is whether the device provides an appropriate spectrum, known irradiance at a realistic working distance, sufficiently uniform light distribution, controllable dosing and a safe protocol for the objective you are pursuing.

Does higher irradiance mean a better effect?

Not automatically. Higher irradiance can reduce the time required to deliver a given radiant exposure, but the biological response to PBM is not simply linear. Dose, irradiance, time, spectrum and target tissue must be considered together.

How far should I stand from a red light panel?

There is no single universal distance. It depends on the optics and irradiance of the specific device, light-field uniformity, treatment area and intended protocol. A recommendation from one manufacturer should therefore not automatically be transferred to another panel.

How many minutes should I use red light therapy?

Time alone does not define the dose. You need at least an approximate understanding of irradiance at the working distance and the protocol for the specific device. A universal rule such as “10 or 20 minutes for everyone” has no scientific basis.

Are more wavelengths better?

Not automatically. What matters is why a particular spectrum is used, what proportion of total output each wavelength represents, and whether the combination is appropriate for the intended application.

Do I need to use a sauna or improve microcirculation before red light therapy?

No. There is no universal evidence that sauna, hydrotherapy or another modality used before PBM is required for it to work or automatically enhances the result. Individual TANVEA Biological Systems™ represent different physical inputs, not a mandatory sequence of procedures.

Why does red light therapy seem to help one person more than another?

Differences may arise from the device, actual dose, objective, tissue optical properties and depth, protocol, consistency and normal biological variability between individuals. A difference in outcome therefore cannot automatically be blamed either on the panel or on an “unprepared body”.

How quickly do results appear?

It depends on the outcome being measured. Some results may be assessed over a short period, while others require weeks or months. The first subjective sensation is not a universal test of efficacy.

Is red light therapy at home safe?

When appropriately used, PBM is generally considered safe, but safety depends on the device, dose, anatomical region and health context. High-output devices should be used according to eye-safety instructions, and individual professional advice is appropriate in cases involving photosensitivity, photosensitising medication or significant medical conditions.


SCIENTIFIC REFERENCES AND EVIDENCE BASE

Song E, Ang L, Yim MH, Choi S, Kim J.
Umbrella review of low-level light therapy: evidence across clinical conditions.
Lasers in Medical Science. 2026;41(1).
DOI: 10.1007/s10103-026-05064-3.
Umbrella review of 100 systematic reviews representing 790 unique primary studies. It identifies potential benefits in selected indications while also highlighting the low methodological quality of a large proportion of reviews, substantial parameter heterogeneity and insufficient reporting of adverse events.

Das RK, Thayer WP, Kubiak CA, et al.
Efficacy and Safety of At-Home Light-Emitting Diode Photobiomodulation for Facial Rejuvenation: A Systematic Review.
Aesthetic Plastic Surgery. 2026.
Systematic review of eight studies involving 365 participants and focusing specifically on at-home LED PBM devices for facial rejuvenation. Findings were favourable overall, but treatment protocols were heterogeneous.

Maghfour J, Mineroff J, Ozog DM, et al.
Evidence-based consensus on the clinical application of photobiomodulation.
Journal of the American Academy of Dermatology. 2025;93(2):429–443.
DOI: 10.1016/j.jaad.2025.04.031.
International multidisciplinary consensus addressing PBM safety and supported clinical indications.

Son Y, Lee H, Yu S, et al.
Effects of photobiomodulation on multiple health outcomes: an umbrella review of randomized clinical trials.
Systematic Reviews. 2025;14:160.
DOI: 10.1186/s13643-025-02902-3.
Umbrella review of 15 meta-analyses, 204 RCTs and more than 9,000 participants. It reports favourable results for selected outcomes while showing predominantly low-to-moderate certainty of evidence across much of the broader evidence base.

Arany PR.
Photobiomodulation therapy.
JADA Foundational Science. 2025.
DOI: 10.1016/j.jfscie.2025.100045.
State-of-the-art review emphasising light–tissue interaction, target-tissue properties, biological objectives, safety and rationalised dosing.

Zein R, Selting W, Hamblin MR.
Review of light parameters and photobiomodulation efficacy: dive into complexity.
Journal of Biomedical Optics. 2018;23(12).
DOI: 10.1117/1.JBO.23.12.120901.
Key review addressing the complexity of wavelength, irradiance, fluence, power, exposure time, pulsing and treatment repetition.

Huang YY, Chen ACH, Carroll JD, Hamblin MR.
Biphasic Dose Response in Low Level Light Therapy.
Dose-Response. 2009;7(4):358–383.
DOI: 10.2203/dose-response.09-027.Hamblin.
Foundational paper on the biphasic dose response in photobiomodulation.

Huang YY, Sharma SK, Carroll J, Hamblin MR.
Biphasic Dose Response in Low Level Light Therapy – an update.
Dose-Response. 2011;9(4):602–618.
DOI: 10.2203/dose-response.11-009.Hamblin.
Updated dose-response model incorporating mitochondrial membrane potential, ATP and redox signalling.

de Freitas LF, Hamblin MR.
Proposed Mechanisms of Photobiomodulation or Low-Level Light Therapy.
IEEE Journal of Selected Topics in Quantum Electronics. 2016;22(3).
DOI: 10.1109/JSTQE.2016.2561201.
Mechanistic PBM framework covering mitochondria, cytochrome c oxidase, nitric oxide, ROS, Ca²⁺ and downstream signalling.

Hamblin MR.
Mechanisms and Mitochondrial Redox Signaling in Photobiomodulation.
Photochemistry and Photobiology. 2018;94(2):199–212.
DOI: 10.1111/php.12864.
Important review of mitochondrial and redox signalling and of differences in cellular responses according to biological state.

Hadis MA, Zainal SA, Holder MJ, et al.
The dark art of light measurement: accurate radiometry for low-level light therapy.
Lasers in Medical Science. 2016.
Highlights inadequate reporting and inaccurate measurement of key radiometric parameters in PBM research.


SAFETY AND NON-MEDICAL DISCLAIMER

This article is intended for informational and educational purposes. TANVEA Light Systems™ and at-home photobiomodulation devices do not replace diagnosis, medical examination or indicated medical treatment.

Specific dose, working distance, frequency and safety requirements depend on the characteristics of the device, the target area and the individual health context. In cases involving photosensitivity, photosensitising medication, significant eye disease, serious medical conditions, or the use of PBM with the intention of influencing a diagnosed disease, it is appropriate to discuss its use with a relevant healthcare professional.

For high-intensity light devices, follow the manufacturer’s instructions regarding eye protection and recommended working distance.


TANVEA EDITORIAL NOTE

This article intentionally distinguishes between technical device quality, optical exposure, biological mechanism and clinical outcome.

TANVEA Biological Systems™ also do not imply that Hydro, Thermal, Light, Oxygen and Hydrogen Systems™ must be used together or in a particular sequence for photobiomodulation to work. Each system represents a distinct physical or biological input, and their shared framework exists to deepen our understanding of the human organism — not to manufacture synergies that have not been demonstrated.

START WITH THE RIGHT QUESTION

If you are considering red light therapy at home, do not begin with:

“Which panel has the most watts?”

Begin with:

“What do I want light to influence, and can this system create a precise, controllable and reproducible exposure appropriate for that objective?”

That is where the difference between buying a light-emitting device and understanding photobiomodulation begins.

At TANVEA Light Systems™, we do not approach light as a competition in intensity. We consider spectrum, actual exposure, geometry, dose, target tissue, safety and biological context.

If you would like to understand these differences through direct experience, you can explore them at TANVEA Experience Space™.

Zdielať:

Autor: Miroslav Tančin

Zakladateľ TANVEA a tvorca konceptu TANVEA Biological Systems™

Ak máte otázky k článku, k biologickým súvislostiam alebo chcete lepšie pochopiť, ktorý TANVEA systém dáva zmysel práve pre vás, môžete mi napísať priamo na tancin@tanvea.com